Meredith M. Regan

机构：Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center · ORCID：0000-0002-2428-6109

发表论文 676 篇 · 总被引 41612 次 · h-index 95

代表论文

• Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy (2025 · The Lancet · 被引 33)
• Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer (2025 · Annals of Oncology · 被引 31)
• National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations (2025 · Journal of Clinical Oncology · 被引 6)
• Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (2026 · Journal for ImmunoTherapy of Cancer · 被引 3)
• Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor–Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study (2025 · Clinical Cancer Research · 被引 3)
• Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer (2026 · The Breast · 被引 2)